| 12 weeks (95% CI) | At all time points of follow-up | At 90% of the time points (95% CI) | At 80% of the time points of follow-up (95% CI) | |
| Partial remission | 7 (18.4%) (9.2 to 33.4) | 3/7 | 5/7 (71.4%) (35.9 to 91.8) | 6/7 (85.7%) (48.7 to 97.4) |
| BASDAI<3 | 21 (55.3%) (39.7 to 69.9) | 12/21 | 16/21 (76.2%) (54.9 to 89.4) | 19/21 (90.5%) (71.1 to 97.3) |
| BASFI<3 | 24 (63.2%) (47.3 to 76.6) | 14/24 | 17/24 (70.8%) (50.8 to 85.1) | 17/24 (70.9%) (50.8 to 85.1) |
| No arthritis | 33 (86.8%) (72.7 to 94.2) | 24/33 | 31/33 (93.9%) (80.4 to 98.3) | 32/33 (97.0%) (84.7 to 99.5) |
| No enthesitis | 29 (76.3%) (60.8 to 87.0) | 14/29 | 25/29 (86.2%) (69.4 to 94.5) | 25/29 (86.2%) (69.4 to 94.5) |
| No arthritis/enthesitis | 28 (73.7%) (58.0 to 85.0) | 14/28 | 22/28 (78.6%) (60.5 to 89.8) | 23/28 (82.1%) (64.4 to 92.1) |
| BASDAI/global assessment <4 | 25 (65.8%) (49.9 to 78.8) | 12/25 | 20/25 (80.0%) (60.9 to 91.1) | 21/25 (84.0%) (65.3 to 93.6) |
| CRP ⩽6 mg/l | 34 (89.5%) (75.9 to 95.8) | 8/34 | 23/34 (67.6%) (50.8 to 80.9) | 27/34 (79.4%) (63.2 to 89.7) |
Numbers are n of patients, numbers in brackets are % of patients.